Glaukos
Market Cap
US$2.7b
Last Updated
2019/09/19 00:32 UTC
Data Sources
Company Financials +
Executive Summary
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma.
Snowflake
Fundamentals
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Glaukos's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0.3%
NYSE:GKOS
0.5%
US Medical Equipment
-0.02%
US Market
1 Year Return
21.2%
NYSE:GKOS
9.9%
US Medical Equipment
1.6%
US Market
GKOS outperformed the Medical Equipment industry which returned 9.7% over the past year.
GKOS outperformed the Market in United States of America which returned 1.9% over the past year.
Share holder returns
| GKOS | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.3% | 0.5% | -0.02% |
| 30 Day | 16.3% | 0.09% | 2.7% |
| 90 Day | -3.2% | 2.0% | 1.4% |
| 1 Year | 21.2%21.2% | 10.8%9.9% | 3.8%1.6% |
| 3 Year | 88.0%88.0% | 69.0%63.9% | 45.2%35.8% |
| 5 Year | n/a | 136.2%109.3% | 61.8%44.1% |
Price Volatility Vs. Market
How volatile is Glaukos's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
What You Must Know About Glaukos Corporation's (NYSE:GKOS) Beta Value1 month ago | Simply Wall St
Are Insiders Selling Glaukos Corporation (NYSE:GKOS) Stock?1 month ago | Simply Wall St
How Should Investors React To Glaukos Corporation's (NYSE:GKOS) CEO Pay?Valuation
Is Glaukos undervalued based on future cash flows and its price relative to the stock market?
14.29x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Glaukos's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Glaukos's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Glaukos is loss making, we can't compare its value to the US Medical Equipment industry average.
Glaukos is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Glaukos, we can't assess if its growth is good value.
Price Based on Value of Assets
Glaukos is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Glaukos expected to perform in the next 1 to 3 years based on estimates from 8 analysts?
98.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Glaukos's revenue is expected to grow by 19.2% yearly, however this is not considered high growth (20% yearly).
Glaukos's earnings are expected to grow significantly at over 20% yearly.
Glaukos's revenue growth is expected to exceed the United States of America market average.
Glaukos's earnings growth is expected to exceed the United States of America market average.
Glaukos's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Glaukos will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Glaukos performed over the past 5 years?
23.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Glaukos does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
Unable to compare Glaukos's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Glaukos's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Glaukos has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Glaukos has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Glaukos improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Glaukos's financial position?
Financial Position Analysis
Glaukos is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Glaukos's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Glaukos has no debt.
Glaukos has no debt compared to 5 years ago when it was 551.1%.
Balance Sheet
High level of physical assets or inventory.
Glaukos has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Whilst loss making Glaukos has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
Whilst loss making Glaukos has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -37.6% per year.
Next Steps
Dividend
What is Glaukos's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Glaukos's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Glaukos's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Glaukos has not reported any payouts.
Unable to verify if Glaukos's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Glaukos has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Glaukos's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Glaukos's salary, the management and board of directors tenure and is there insider trading?
2.6yrs
Average management tenure
CEO
Thomas Burns (58yo)
17.5yrs
Tenure
US$5,198,717
Compensation
Mr. Thomas William Burns has been the Chief Executive Officer and President at Glaukos Corporation since march 2002. He served as Director of Avedro, Inc. since July 18, 2018 until August 06, 2019. Prior t ...
CEO Compensation Analysis
Thomas's remuneration is about average for companies of similar size in United States of America.
Thomas's compensation has increased whilst company is loss making.
Management Age and Tenure
2.6yrs
Average Tenure
58yo
Average Age
The tenure for the Glaukos management team is about average.
Board Age and Tenure
5.2yrs
Average Tenure
58yo
Average Age
The tenure for the Glaukos board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman of the Board Chairman |
| Shares | 41,500 |
| Max Price | US$58.18 |
Ownership Breakdown
Management Team
Robert Davis (53yo)
Senior VP
- Tenure: 4.3yrs
Jane Rady (71yo)
Senior Vice President of Corporate Strategy & Business Development
- Tenure: 1.4yrs
Mory Gharib
Co-Founder
- Tenure: 0yrs
L. Katz
Chief Medical Officer
- Tenure: 2.6yrs
Chris Lewis
Director of Investor Relations
- Tenure: 0yrs
Thomas Burns (58yo)
CEO, President & Director
- Tenure: 17.5yrs
- Compensation: US$5.20m
Chris Calcaterra (59yo)
Chief Operating Officer
- Tenure: 2.6yrs
- Compensation: US$1.96m
David Haffner
Senior Vice President of New Technologies
- Tenure: 2.6yrs
Michele Allegretto
Senior Vice President of Human Resources
- Tenure: 4.3yrs
Joe Gilliam (43yo)
CFO & Senior VP of Corporate Development
- Tenure: 2.3yrs
- Compensation: US$1.95m
Board Members
Bill Link (73yo)
Chairman
- Tenure: 18.3yrs
- Compensation: US$264.99k
Richard Lindstrom (71yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
Aimee Weisner (50yo)
Director
- Tenure: 5.2yrs
- Compensation: US$224.99k
Mark Foley (54yo)
Director
- Tenure: 5.2yrs
- Compensation: US$234.99k
David Hoffmeister (64yo)
Director
- Tenure: 5.2yrs
- Compensation: US$232.48k
Thomas Burns (58yo)
CEO, President & Director
- Tenure: 17.5yrs
- Compensation: US$5.20m
Ike Ahmed
Member of Scientific Advisory Board
- Tenure: 0yrs
Thomas Samuelson
Member of Scientific Advisory Board
- Tenure: 0yrs
Marc Stapley (49yo)
Director
- Tenure: 5.2yrs
- Compensation: US$243.99k
Rick Lewis
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Glaukos Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Glaukos Corporation
- Ticker: GKOS
- Exchange: NYSE
- Founded: 1998
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$2.698b
- Shares outstanding: 36.83m
- Website: https://www.glaukos.com
Number of Employees
Location
- Glaukos Corporation
- 229 Avenida Fabricante
- San Clemente
- California
- 92672
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GKOS | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 2015 |
| 6GJ | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2015 |
Biography
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to tre ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/19 00:32 |
| End of Day Share Price | 2019/09/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.